ASH 2024 | Efficacy of frontline ponatinib plus blinatumomab for adult Ph+ ALL: analysis of GIMEMA ALL2820
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, comments on the efficacy and toxicity of frontline ponatinib plus blinatumomab for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), noting that the GIMEMA ALL2820 trial (NCT04722848) has achieved impressive results, including a complete remission rate of 96% and overall survival and disease-free survival rates of approximately 95%. Dr Chiaretti highlights that the trial’s chemotherapy-free strategy has reduced the incidence of adverse events and transplant-related mortalities, and that the majority of deaths and relapses occurred during induction, primarily in elderly patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
